ijms-logo

Journal Browser

Journal Browser

Molecular Mechanisms and New Therapies for Breast Cancer: 2nd Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (30 June 2025) | Viewed by 939

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
Interests: cancer biology; molecular and cell biology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The goal of this Special Issue is to summarize new knowledge in breast cancer signaling and its implications for developing new therapeutics. There have been significant developments in managing breast cancer and metastatic progression in the last decade. This Special Issue will focus on reviewing recent clinical trial data that indicate the effectiveness of chemotherapy combinations with immunotherapies. We will entertain manuscripts focused on addressing the challenges in bringing new biomarkers from benchside to bedside. This Special Issue will address the concerns of breast cancer patient advocates in regard to current practices of breast cancer treatments. Overall, the Special Issue will serve as a common platform for basic scientists, bioinformaticians, statisticians, and surgical oncologists to discuss the recent advances in new breast cancer therapies that can promote an agenda for key research needs in this area for the next 5–10 years.

All research article submissions should involve research at the molecular level in addition to well-found verified experiments. Clinical trials and animal as well as cell testing are eligible only if they are strongly needed to support hypotheses or theories concerning structure–function correlations, and are not suitable if no molecular aspects are considered.

Prof. Dr. Mary Lou Cutler
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • management of metastatic disease
  • neoadjuvant therapy
  • chemotherapy and immunotherapy combination
  • novel biologics
  • aromatase inhibitors
  • outcome research
  • quality of life during and after breast cancer therapy
  • new targets for TNBC

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 1911 KB  
Article
Targeting Voltage-Gated Potassium Channels in Breast Cancer: Mechanistic Insights into 4-Aminopyridine-Induced Cell Death
by Esra Münire Cüce-Aydoğmuş, Pınar İyiol and Günseli Ayşe İnhan-Garip
Int. J. Mol. Sci. 2025, 26(16), 7768; https://doi.org/10.3390/ijms26167768 - 12 Aug 2025
Viewed by 718
Abstract
Cancer has recently been proposed as a type of channelopathy due to the aberrant expression of various ion channels. Voltage-gated potassium (K+) channels (VGKCs) are notably upregulated during tumor proliferation, while voltage-gated sodium (Na+) channels are predominantly associated with [...] Read more.
Cancer has recently been proposed as a type of channelopathy due to the aberrant expression of various ion channels. Voltage-gated potassium (K+) channels (VGKCs) are notably upregulated during tumor proliferation, while voltage-gated sodium (Na+) channels are predominantly associated with the invasive stage of cancer progression. Among these, the Kv10.1 channel has been found to be overexpressed in breast cancer, making it a promising therapeutic target. 4-Aminopyridine (4-AP), a non-selective voltage-gated potassium channel blocker, has emerged as a potential novel agent for breast cancer treatment. In this study, we aimed to elucidate the mechanism of action of 4-aminopyridine in breast cancer cells. To investigate the involvement of various cell death pathways, cycloheximide (CHX) (a paraptosis inhibitor), Z-VAD-FMK (a pan-caspase inhibitor), and 2-Aminoethoxydiphenyl borate (2-APB) (a phosphoinositide 3-kinase [PI3K] inhibitor) were employed. Experiments were conducted using the MCF-7 human breast cancer cell line and the L929 mouse fibroblast cell line as a healthy control. Assessments included cell viability assays, intracellular calcium (Ca2+) and K+ concentration measurements, and plasma membrane potential analysis. Our findings aim to contribute to the understanding of the therapeutic potential and cellular effects of VGKC blockers, particularly 4-aminopyridine, in breast cancer treatment strategies. Full article
(This article belongs to the Special Issue Molecular Mechanisms and New Therapies for Breast Cancer: 2nd Edition)
Show Figures

Figure 1

Back to TopTop